Expedited Review of New Drugs or New Indications for Drugs In the Six Classes of Clinical Concern Reminder
Guidance for expedited review process requires P&T committees to make a decision within 90 days, rather than the normal 180-day requirement. As a result, these new drugs or new indications for drugs now within the six classes of clinical concern need to be reviewed and acted upon by P&T committees within 90 days of release onto the market.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: July 21, 2006
HHS is committed to making its websites and documents accessible to the widest possible audience, including individuals with disabilities. We are in the process of retroactively making some documents accessible. If you need assistance accessing an accessible version of this document, please reach out to the guidance@hhs.gov.
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.